Latatim (Timolol Maleate, Latanoprost)

Timolol maleate blocks beta‑adrenergic receptors in the eye, reducing aqueous humor production. Latanoprost activates prostaglandin F2α receptors, increasing uveoscleral outflow of fluid. Together they provide a complementary reduction of intraocular pressure.

The dosing regimen for Latatim is determined by the prescribing ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily, but the exact frequency and quantity are individualized based on patient response and clinical judgment.

Safety data for Latatim in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Latatim, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latatim combines a beta‑blocker and a prostaglandin analog, offering dual mechanisms in a single bottle. Compared with monotherapy agents, it can achieve greater pressure reduction, potentially simplifying treatment regimens and improving adherence versus using separate drops.

Latatim eye drops should be stored at room temperature, below 25 °C, in the original packaging. Protect the bottle from direct sunlight and moisture, and keep the cap tightly closed when not in use.

Latatim is applied as an ocular solution. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of each prescribed eye, avoiding contact between the tip and the eye or any surface.

Serious risks include severe allergic reactions affecting the eyelid or surrounding tissue, systemic beta‑blocker effects such as bradycardia or hypotension, and excessive lowering of intraocular pressure that could compromise ocular perfusion.

Latatim is contraindicated in patients with known hypersensitivity to timolol, latanoprost or any excipients, in individuals with severe asthma, certain cardiac conduction disorders, and in eyes with active intraocular inflammation or infection.